– Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation – Senior commercial executives of Trinity...
MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select...
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United StatesSAN DIEGO, Feb....
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb....
Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...
- Apothecare calls for medical cannabis education to be integrated into clinical training and standard practice, not left to patients...
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over...
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and...
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ETWALTHAM, Mass., Feb. 10, 2026 (GLOBE...
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease,...
BANGALORE, India, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Emerging clinical data underscores the efficacy of Natural Remedies’ Ashwa.30, a low-dose, clinically...
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a...
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth...
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing...
FRISCO, Texas and CHESTERFIELD, Mo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of...
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a...
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for...
Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China...
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT...